News

Gilead’s Trodelvy with Merck’s Keytruda cuts disease progression/ death in breast cancer
Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Boston Scientific leads in MedSurg and Cardiovascular with strong Q1 growth, solid margins, and smart acquisitions. Find out ...
StockStory.org on MSN2d
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
Fintel on MSN3d
Goldman Sachs Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Neutral Recommendation
Fintel reports that on May 29, 2025, Goldman Sachs initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...
Stocks to Watch: Nvidia, HP, Taysha Gene Therapies
Taysha Gene Therapies disclosed details of a planned trial for its treatment for Rett syndrome and filed for a secondary share offering. The biotechnology company said its Part B trial for TSHA-102, ...
Taysha Gene Therapies Stock Rises on Trial Design, Secondary Share Offering
Shares of Taysha Gene Therapies climbed after the company announced details of a planned trial for its treatment for Rett syndrome and filed for a secondary share offering. The stock rose 13% to $2.76 ...
STAT4d
Pharmalittle: We’re reading about a biotech IPO slump, FDA oversight of pharma ads, and more
U.S. senator wants to know how the FDA will enforce drug ad regulations after letting go numerous workers from the office ...
Investorideas.com5d
Breaking Gold Stock News - Gravity Separation Circuit Delivered to Montauban as ESGold (CSE: ESAU) (OTCQB: ESAUF) Advances Toward Production
Explore the best investing ideas for 2025 at Investorideas.com. Get stock news, podcasts, videos, and insights on AI, crypto, ...